

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	NA

## Yosprala (aspirin delayed-release/omeprazole)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Yosprala (aspirin delayed-release/omeprazole)	May be subject to quantity limit

### APPROVAL CRITERIA

Requests for Yosprala (aspirin delayed-release/omeprazole) may be approved when the following criteria are met:

- I. Documentation of medical necessity for Yosprala (aspirin delayed-release/omeprazole) is provided to define the inadequate response to the agents when used separately; **AND**
- II. The medical reason the combination agent is clinically necessary is provided.

Requests for Yosprala (aspirin delayed-release/omeprazole) may not be approved for the following:

- I. Individual with the syndrome of asthma, rhinitis and nasal polyps; **OR**
- II. Individual with any hepatic impairment (Child Pugh Class A, B or C); **OR**
- III. Individual with severe renal impairment (eGFR < 10 mL/min).

### Key References:

1. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: December 26, 2019.
2. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
3. Kernan WN, Ovbiagele B, Black HR et. al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association (AHA/ASA). *Stroke*. 2014;45(7):2160-2236.

CRX-ALL-0543-20

PAGE 1 of 2 04/24/2020  
New Program Date 05/16/2017

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
<b>Applicable</b>	X	X	X	X	X	X	NA

4. Lansberg MG, O'Donnell MJ, Khatri P et. al. Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians (ACCP) Evidence-Based Clinical Practice Guidelines. *Chest*. 2012;141(2 Suppl):e601S-e636S.
5. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2019; Updated periodically.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.